Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Public ClinicalTrials.gov record NCT00982488. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Study identification
- NCT ID
- NCT00982488
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 238 participants
Conditions and interventions
Conditions
Interventions
- Dasatinib Drug
- Imatinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2007
- Primary completion
- Nov 30, 2014
- Completion
- Nov 30, 2014
- Last update posted
- Jan 21, 2016
2007 – 2014
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pacific Cancer Medical Center Inc | Anaheim | California | 92801 | — |
| Loma Linda University Cancer Center | Loma Linda | California | 92354 | — |
| Ucla Department Of Medicine | Los Angeles | California | 90095 | — |
| Stanford University School Of Medicine | Stanford | California | 94305 | — |
| Kaiser Permanente Medical Center | Vallejo | California | 94589 | — |
| H. Lee Moffitt Cancer Center & Research Institute | Tampa | Florida | 33612 | — |
| University Of Chicago | Chicago | Illinois | 60637 | — |
| Central Indiana Cancer Centers | Indianapolis | Indiana | 46219 | — |
| University Of Kansas Medical Center | Westwood | Kansas | 66205 | — |
| Dana Faber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University Of Michigan Medical Center | Ann Arbor | Michigan | 48109 | — |
| Wayne State University | Detroit | Michigan | 48201 | — |
| John Theurer Cancer Center | Hackensack | New Jersey | 07601 | — |
| Oregon Health & Sci Univ | Portland | Oregon | 97239 | — |
| Western Pennsylvania Hospital | Pittsburgh | Pennsylvania | 15224 | — |
| Ut Southwestern Medical Center At Dallas | Dallas | Texas | 75390 | — |
| The University Of Texas Md Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 55 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00982488, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 21, 2016 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00982488 live on ClinicalTrials.gov.